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Iloprost treatment in patients with Raynaud’s
phenomenon secondary to systemic sclerosis and
the quality of life: a new therapeutic protocol
G. Milio, E. Corrado, C. Genova, C. Amato, F. Raimondi,
P. L. Almasio1 and S. Novo
Objectives. To evaluate the clinical efﬁcacy and the effects on the quality of life of iloprost, a prostacyclin analogue, used
according to a new protocol in patients with Raynaud’s phenomenon secondary to systemic sclerosis.
Methods. In this randomized study, we treated 30 patients with iloprost, given by intravenous infusion, at progressively
increasing doses (from 0.5 to 2 ng/kg/min) over a period of 6 h each day for 10 days in two consecutive weeks, with repeated
cycles at regular intervals of 3 months for 18 months. The results were compared with those obtained in 30 other patients who
received the same drug but with different dosing schemes.
Results. The total average daily duration of the attacks, the average duration of a single attack and the average daily frequency
of the attacks were reduced signiﬁcantly in all treatment groups, but the comparison between the groups demonstrated
signiﬁcant differences between patients treated with the new protocol and the others at later times (12 and 18 months). The
effects on the quality of life in the group treated with the new protocol, evaluated with the Short Form-36, demonstrated
a marked improvement regarding both the scale relating to the physical aspect of the illness and, especially, the scale relating
to the mental aspect.
Conclusions. In patients with systemic sclerosis, cyclic intravenous iloprost infusion is efﬁcacious in the treatment of Raynaud’s
phenomenon. The protocol that we used, compared with others, not only has favourable clinical effects but also leads to
a marked improvement in the quality of life.
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Systemic sclerosis (SSc), as is well known, is a condition of the
connective tissue, characterized by obliterative vascular lesions
that affect, above all, the small vessels, and the involvement in the
advanced stages of various organs and apparatus [1–3].
In most cases, the precocious clinical manifestations are
acrovascular and manifest themselves as Raynaud’s phenomenon;
in more advanced phases, there are necrotic and/or ulcerative
ischaemic lesions [4]. Often Raynaud’s phenomenon precedes,
perhaps by several years, the clinical onset of the illness [5–7]. Its
physiopathological mechanism is still not clear [8], but some
factors are clearly evident: structural and functional alterations of
the endothelium with reduced production of nitric oxide and
prostacyclin [9–11]; activation of white cells with the release of
free O2 radicals [12, 13]; and platelet activation, with an increase
in viscosity and aggregation.
The treatment of systemic sclerosis, in particular the vascular
manifestations, includes the following objectives: the reduction of
vasospastic phenomena; improvement in vascular permeability,
counteracting endothelium dysfunction and leucocyte migration;
control of the haemorheological component, also by an anti-
platelet action; the prevention of visceral involvement; and
improvement in the quality of life.
Many substances may be used to achieve these aims. Among
these, a synthetic form of prostacyclin, iloprost, is the most
promising as it is able to carry out numerous actions, as reported
in Table 1 [14–17].
Several studies have shown the effectiveness of iloprost in the
treatment of the vascular manifestations of SSc using different but
equally effective protocols [18–22]. Because there is no standard
protocol, we need a therapeutic one that is distinguished by its
effectiveness in improving the quality of life, because we are
concerned with chronic patients treated day by day throughout
their life [23, 24].
The objective of this study was to evaluate the validity of a new
protocol, taking into consideration not only the clinical efﬁcacy
of the drug with respect to the vascular manifestations of SSc, but
also its effects on the quality of life.
Methods
Study design and treatment
The protocol provides for the intravenous administration, by
means of a peristaltic pump, of iloprost at progressively increasing
doses (from 0.5 to 2 ng/kg/min) for 6 h a day. The treatment
proceeds for 10 days for two consecutive weeks (5 consecutive
daysþ 2 days of interruptionþ 5 consecutive days) with repeated
cycles four times a year at regular intervals of 3 months.
Thirty patients suffering from SSc with secondary FR were
treated during a 2-yr period with the protocol described above
(group A). They were compared with 30 other patients with
a similar disease who had received different dosing schemes of the
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drug, administered by the same means: 15 of them were given
an infusion each month (group B1), according to one of the
more commonly used protocols, and the others were given
20 consecutive infusions every 6 months (group B2), according
to a protocol that we have used in the past.
The patients were randomized with an allocation sequence
obtained using a random-number table (sealed envelops).
The study used a prospective, controlled, open design with
parallel groups, and was performed between February 2003 and
March 2005. It complied with the Consolidated Standards of
Reporting Trials (CONSORT) statement [25]. The protocol was
approved by the appropriate ethics committee of the University
Hospital P. Giaccone of Palermo.
Patients
We enrolled patients suffering from SSc, with either diffuse or
limited skin disease, with secondary Raynaud’s phenomenon (RP).
The diagnosis of SSc was made according to criteria described by
Le Roy et al. [3]. The diagnosis of RP was based on a history of
episodic digital pallor and/or cyanosis in response to cold exposure
or emotional stress, and was conﬁrmed by capillaroscopic
examination. Males and females were included and all patients
were at least 18 yr old. Also, they had to have an average of at least
eight Raynaud’s attacks per week.
Exclusion criteria were pregnancy, the presence of platelet
alterations, the occurrence of AMI, unstable angina, strokes and
TIA within the past three months, surgical sympathectomy in the
last 12 months, and the presence of RP connected to other
pathologies.
Calcium antagonist drugs, -blockers and other vasodilators
used for the treatment of RP were suspended at least a month
before the infusion period, while angiotensin-converting enzyme
inhibitors and calcium antagonists used for the treatment of
accompanying arterial hypertension were maintained with the
same dosing scheme for the duration of the study.
All patients were informed about the nature and aim of the
study, and provided written consent to their participation in
the study.
Procedures, outcomes and measurement
All patients were submitted to clinical and instrumental evaluation
to deﬁne their characteristics and any possible subtypes. Patients
with serious organ damage were excluded.
On admission, all subjects underwent a medical examination
and also answered a questionnaire on personal and medical items,
including age, past medical history and the use of medications.
Digital cutaneous lesions were recorded before the start of
the study. Patients underwent: capillaroscopy, barium oeso-
phagography, echocardiography, myocardial scintigraphy, chest
radiography, high-resolution renal sonography; and laboratory
tests comprising determination of immunoglobulins (Ig) A, G and
M, testing for autoantibodies ANA, ACA, anti-double-stranded
DNA, anti-Scl70 (anti-topoisomerase), anti-SSA, anti-SSB,
anti-SM, anti-RNP and anti-Jo1.
Table 2 shows the baseline characteristics of the patients.
The clinical outcomes were the duration, number and severity
of Raynaud’s attacks, which were recorded in a diary kept by
the patients. Each patient had to record the number of crises each
day, as well as the duration of each attack and its severity on
a visual analogical scale 10 cm long.
From an analysis of the daily record sheets, we calculated the
following: (i) the total average daily duration of the attacks
(TADDA), obtained by dividing the total duration in min of
attacks during a given two-week intervel (observation period) by
the number of diary days; (ii) the average duration of a single
attack (ADSA), by dividing the overall duration by the number of
attacks during the observation period; (iii) the average daily
frequency of the attacks (ADFA), by dividing the total number of
attacks during the interval considered (2 weeks) by the number of
diary days; and (iv) the severity of the attacks, measured on a visual
analogical scale; this was designated the Raynaud’s condition score
(RCS) and was calculated as the arithmetic average of the daily
scores during the interval considered (2 weeks).
Tests were made on all the groups under treatment before
the start (T0), and after 3 months (T3), 6 months (T6), 12 months
(T12) and 18 months (T18).
The effects on the quality of life were evaluated by means of
the Short Form-36 (SF-36), taking into account eight parameters
according to a scale from 0 to 3 (physical activity, physical health,
physical pain, social activity, emotive state, mental health, general
health, and vitality) [26–28]. The ﬁndings relative to the test were
done at times T0, T6, T12 and T18 in the various groups.
The tolerability of the drug was studied by means of clinical
parameters, making note of any symptoms present in the
patient and measuring arterial pressure before, during and at
TABLE 1. Pharmacological effects of iloprost
Inhibition of platelet adhesiveness and aggregation, interacting with
receptors of prostacyclin
Inhibition of proliferation of smooth muscle cells of the media
Proﬁbrinolytic activity
Vasodilator effect, with consequent improvement of the microcirculatory
ﬂow
Inhibition of chemotaxis and activation of white cells
Reduction of expression of adhesion molecules
Reduction of production of superoxide anion by leucocytes
Inhibition of the platelet–leucocyte interaction
Stimulation of formation and growth of collateral circulation
Restoration of the equilibrium between the system regulating
microvascular ﬂow and the microvascular defence system,
with a reduction in endothelial permeability and inhibition of the
vasoconstrictive activity of thromboxane A2, serotonin,
leukotrienes and endothelins
TABLE 2. Patients’ characteristics at baseline
Group A Group B1 Group B2
Number of patients 30 15 15
Age, yr: mean (S.D.) 39 (21) 40 (21) 39 (20)
Sex: no. of females (%) 25 (83) 12 (80) 12 (80)
Smokers: no. (%) 13 (43) 8 (53) 7 (46)
Clinical history
Time since appearance of
illness: yr (S.D.)
6 (3) 5 (4) 6 (4)
Weekly frequency of the attacks: no. >8 >8 >8
Clinical features
Ulcers: no. (%) 6 (20) 3 (20) 3 (20)
Oesophagus alterations: no. 1 – 1
Myocardial alterations: no. – – –
Pulmonary hypertension: no. – – –
Renal alterations: no. – – –
Laboratory features
Immunological alterations: no. (%) 24 (80) 13 (86) 13 (86)
Increase in ANA: no. (%) 20 (66) 9 (60) 8 (53)
Increase in ACA: no. (%) 19 (63) 8 (53) 8 (53)
Increase in anti-Scl 70
antibodies: no. (%)
4 (13) 2 (13) 3 (20)
Increase in anti-RNP
antibodies: no. (%)
7 (23) 4 (26) 2 (13)
Capillaroscopic changes: no. (%) 26 (86) 13 (86) 14 (93)
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the end of each infusion, as well as with laboratory parameters.
In this way the main haematochemical and haemocoagulative
parameters were determined at the beginning and end of each
infusion cycle, and at regular 6-month intervals.
Sample size and statistical analysis
To detect a decrease of 20% in the mean total duration of
daily attacks (a reduction considered to be clinically
relevant), the number to be included was 14 subjects per arm
(, 0.05; , 0.10).
Because we compared two standard regimens (groups B1
and B2), we included twice the number of patients in the
experimental arm.
Statistical analysis was performed on the data using the
Statview Program (Abacus Concepts).
Means and standard deviations were calculated for the
total daily duration, single duration, frequency and severity of
Raynaud’s attacks; the differences were analysed by means of
Student’s t-test for paired data to compare with basal values
the results at the various observation times, in each treatment
group, and by means of Student’s t-test for unpaired data to
compare the various groups.
Clinical changes were assessed as percentage variations in the
clinical parameters and, regarding the effects on the quality of life,
the parametric scales of the SF-36 were compared using Student’s
t-test for unpaired data [29].
P values less than 0.05 were considered signiﬁcant.
Results
All the patients in each group completed all cycles of infusion
treatment.
The total average daily duration of the attacks (TADDA),
whose basal values did not present differences between the groups,
were reduced signiﬁcantly both in group A and in the control
groups. In particular, in group A the percentage reduction settled
down to around 40% after 3 and 6 months (39.9 and 43.1%,
respectively), becoming more noticeable later (50.0% at T12 and
51.1% at T18). More or less the same values were observed in the
patients of group B1 at 3 and 6 months (reductions of 38.2 and
1.3%, respectively); the later results regarding the percentage
difference were less relevant with respect to group A (47.2% at T12
and 44.6% at T18). In group B2, on the contrary, the differences in
values between the starting times and those further on were less
relevant (22.7% at T3, 18.7% at T6, 23.8% at T12, 21.0% at T18)
(Fig. 1A). The comparison between the groups demonstrated a
statistically signiﬁcant difference between group A and group B2,
especially at T6, T12 and T18 (Table 3).
The average duration of a single attack (ADSA) showed similar
behaviour; it was reduced signiﬁcantly in all groups and at various
observation times: the percentage differences with respect to base
values were more or less the same in group A (differences ranging
between 28.6 and 37.7%) and in group B1 (between 28.2 and
39.0%), but were noticeably smaller in group B2 (between 16.1
and 23.3%) (Fig. 1B). The statistical comparison between the
groups at various times shows signiﬁcant differences at the later
times (T12 and T18) between group A and group B2 (Table 4).
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FIG. 1. Changes from baseline in (A) total average daily duration of attacks (TADDA), (B) average duration of single attacks
(ADSA), (C) average daily frequency of attacks (ADFA) and (D) severity of attacks (RCS).
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The average daily frequency of attacks (ADFA) was reduced
signiﬁcantly in all groups with respect to the base values, with
a difference of 16.2–23.3% in group A, 12.8–16.5% in group B1
and 6.2–10.3% in group B2 (Fig. 1C). Signiﬁcant differences
were observed between groups A and B2 at T6 and at later times
between group A and groups B1 and B2 groups (Table 5).
Finally, regarding the severity of the attacks, measured on a
visual analogical scale and identiﬁed as RCS, there was a marked
improvement in groups A and B1 regarding both the percentage
difference from baseline scores (Fig. 1D) and the statistical
signiﬁcances at the different observation times. Group B2, on the
other hand, recorded a signiﬁcant improvement with respect to
the basal levels, but there was a less evident reduction in scores
such as percentage difference. Moreover, at T6, T12 and T18, there
was a statistically signiﬁcant difference between group A and
group B2 (Table 6).
To measure quality of life, we preferred to use the SF-36, which
has the advantage over other instruments, such as the Health
Assessment Questionnaire (HAQ) and the Systemic Sclerosis
Questionnaire (SysQ), of evaluating not only physical health
but also mental health, and of minimizing the workload of the
subject undergoing the interview, so long as only eight parameters
are considered, without reducing the precision of the ﬁndings [30].
Table 7 shows the baseline means for the parameters we considered
in the three groups of patients. According to the above-mentioned
method, we grouped the eight scales into three classes that
represented the physical aspect of the illness, the mental aspect
and general health, by summing the scores of the single scales in
each class.
Figure 2 shows the percentage variations from baseline of the
scale scores constituting the questionnaire and the statistical
comparison between the groups. The scale describing the physical
aspect of the illness, including physical activity, physical health
and physical pain, shows a marked improvement, especially at T12
and T18, in group A, signiﬁcantly greater than in groups B1 and
B2. Similar behaviour is shown by the scales that evaluate general
health and vitality. The scales which evaluate the mental aspect
show a signiﬁcant difference between group A and the other two
groups, not only at later time points but also at the earlier times;
moreover, the percentage changes from baseline were much greater
than in the other classes.
No signiﬁcant differences were observed between the groups
undergoing treatment regarding adverse events, which had the
same intensity and frequency in all groups, particularly for
headaches, nausea and skin rashes. The adverse events reported
were not serious enough to interrupt treatment.
We did not observe any signiﬁcant alteration in the clinical
or laboratory parameters in any of the patients.
Discussion
The efﬁcacy of iloprost in the treatment of vascular manifestations
of systemic sclerosis, above all RP, has been noted for some time,
as reported in numerous studies [18–24].
Endothelial dysfunction and alteration of the normal regula-
tion of the local blood ﬂow that are present in SSc beneﬁt from
therapy using iloprost because of its capacity to inhibit platelet
and leucocyte activation, and consequently to favour tissue repair.
This also explains how the vascular effects and the improvement
in the clinical condition of these patients persist for a long time
after the end of the treatment, as the vasospasm is correlated
to endothelium damage and not exclusively to a functional
phenomenon.
Knowing the long-term beneﬁts of treatment with iloprost,
the objectives of this randomized study were to establish whether
there were differences in the times of efﬁcacy of different
dosing schemes and then to establish a protocol for the scheme
that had the most favourable effect on the quality of life.
Our data demonstrate that the average daily duration of attacks
is signiﬁcantly reduced regardless of the protocol used, but the
persistence of the effects is maximum up to 8–10 weeks, as
demonstrated by the different results for the patients of group A
and group B1 compared with those of group B2, in which after
TABLE 3. Total average daily duration of attacks (TADDA)
Duration (min)
Observation time
(months)
Group A
(n¼ 30)
Group B1
(n¼ 15)
Group B2
(n¼ 15)
T0 72.3±22.9 73.1±23.6 71.4±22.4
T3 43.4±15.4 43.1±14.6 51.7±15.0
T6 41.1±14.1 42.9±14.5 58.1±17.2**
T12 36.1±11.1 38.5±11.1 54.4±14.8**
T18 35.3±11.0 40.5±10.5 56.4±15.2**
Data are mean±S.D.
Groups B1 and B2 vs group A: *P<0.05; **P<0.01.
TABLE 4. Average duration of single attacks (ADSA)
Duration (min)
Observation time
(months)
Group A
(n¼ 30)
Group B1
(n¼ 15)
Group B2
(n¼ 15)
T0 20.9±5.7 20.8±6.6 23.4±7.6
T3 14.7±4.7 14.9±5.2 17.9±5.9
T6 14.5±4.5 14.0±5.0 19.2±6.2
T12 13.3±3.9 12.8±4.5 18.7±6.2*
T18 12.8±3.8 13.4±4.4 19.6±6.2*
Data are mean±S.D.
Groups B1 and B2 vs group A: *P<0.05; **P<0.01.
TABLE 5. Average daily frequency of attacks (ADFA)
Number of attacks per day
Observation time
(months)
Group A
(n¼ 30)
Group B1
(n¼ 15)
Group B2
(n¼ 15)
T0 3.5±0.9 3.4±0.7 3.2±0.8
T3 2.9±0.7 2.9±0.6 2.8±0.6
T6 2.8±0.7 2.8±0.6 3.0±0.5*
T12 2.6±0.6 3.0±0.5* 2.9±0.6*
T18 2.7±0.5 3.0±0.5* 2.8±0.6**
Data are mean±S.D.
Groups B1 and B2 vs group A: *P<0.05; **P<0.01.
TABLE 6. Severity of attacks
Severity as Raynaud’s condition score
(visual analogue scale)
Observation time
(months)
Group A
(n¼ 30)
Group B1
(n¼ 15)
Group B2
(n¼ 15)
T0 4.3±0.5 4.3±0.6 4.1±0.6
T3 3.2±0.5 3.0±0.5 3.1±0.6
T6 2.9±0.5 2.9±0.5 3.7±0.5**
T12 2.7±0.5 3.0±0.4 3.6±0.5**
T18 2.7±0.5 2.9±0.5 3.7±0.5**
Data are mean±S.D.
Groups B1 and B2 vs group A: *P<0.05; **P<0.01.
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6 months there was a reduction in the total average daily duration
of the attacks of 18% of the basal values, compared with around
40% in the other two groups. These effects were then consolidated
with successive cycles of therapy.
The average frequency of the attacks, which expresses the
number of daily crises and was characterized in these patients by
notable variability, demonstrates a minor efﬁcacy in the average
time of protocol B2 compared with the others. However, after a
longer period of time, a difference also emerged between the other
two groups to the advantage of group A. This is probably
connected to the fact that an overall larger quantity of active
substance reduces the chances of an asphyxial crisis, which, once
started, lasted just as long in the two groups. This was conﬁrmed
by the RCS data, which showed the same severity of attacks in all
groups.
Major differences between the various therapeutic protocols
are revealed in the evaluations of the effects on the quality of life;
this is an important parameter in health-care management.
Health is deﬁned not only as the absence of disease but also as a
state of comfort: the quality of life of a patient must be considered
and measured in the context of a complex system that includes
physical, social and mental aspects. Particularly in patients with
SSc, the opinion of the patient is important. The method we used to
evaluate the quality of life in patients with SSc was the SF-36,
which reﬂects the opinion of the patient about the severity of the
illness and his or her physical and mental well-being; other
instruments, such as the questionnaire of Silman [31] and the
Systemic Sclerosis Questionnaire (SySQ) [32], are based exclusively
on the evaluation of the disability.
The data of our study show that, regarding the physical
dimension of the illness and general health, there was an
improvement in the patients in group A, with signiﬁcant differ-
ences compared with group B2 especially. On the other hand, for
the mental dimension of the illness, which is related mainly to
social activity and the emotive state, there was a greater improve-
ment in the group A patients, with signiﬁcant differences compared
with groups B1 and B2.
These results, which reﬂect greater compliance by the patient,
in our opinion, are extremely important if we consider that the
state of health of an individual is not only measured in terms of
physical well-being but also takes into account the psychic element.
This would lead us to prefer our protocol of treatment in patients
TABLE 7. Baseline means and standard deviations of the SF-36 in the three group of patients
PA PH PP GH V SA ES MH
Group A 59±10 37±10 45±11 30±11 48±18 68±11 59±9 65±16
Group B1 62±13 36±7 44±14 32±9 47±18 66±15 57±8 63±13
Group B2 60±9 35±9 43±10 31±12 46±17 65±13 55±9 64±11
PA, physical activity; PH, physical health; PP, physical pain; GH, general health; V, vitality, SA, social activity; ES, emotive state; MH,
mental health.
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FIG. 2. Change from baseline in main outcomes at different times in the three groups.
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suffering from systemic sclerosis, which consists of 10-day cycles
every 3 months; we must also consider that judgements about
the validity of the effects of a therapeutic intervention must take
into account the opinion and the compliance of the patient.
Finally, the monetary cost of treatment using the protocol
proposed (A) is the same as that of protocol B2 and slightly greater
than the that of protocol B1. However, protocol A may have
a favourable cost-beneﬁt ratio even though the monetary cost is
quite high. The improvement in the quality of life, especially
regarding the mental dimension, produced by our proposed
treatment protocol, gives it a favourable socio-economic character
and leads to a quicker return to work.
The authors have declared no conﬂicts of interest.
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Key messages
 The improvement in quality of life,
considered as physical well-being as
psychic healthy, is one of the most
important objectives of the treatment of
systemic sclerosis.
 Compliance with the protocol that we
used in the treatment of patients with
Raynaud’s phenomenon secondary to
systemic sclerosis was better than com-
pliance with other protocols.
1004 G. Milio et al.
